أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; propylene glycol; hypromellose; sodium starch glycollate; maize starch; purified talc; macrogol 6000; magnesium stearate; titanium dioxide; povidone - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; purified talc; colloidal anhydrous silica; povidone; titanium dioxide; sodium starch glycollate; propylene glycol; hypromellose; maize starch - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; magnesium stearate; carmellose sodium - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. diaformin xr may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: hypromellose; purified talc; colloidal anhydrous silica; magnesium stearate; copovidone; propylene glycol; titanium dioxide; arginine; iron oxide yellow; maize starch; iron oxide red - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: arginine; magnesium stearate; purified talc; copovidone; maize starch; iron oxide yellow; titanium dioxide; colloidal anhydrous silica; hypromellose; propylene glycol; iron oxide red - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; iron oxide yellow; hypromellose; titanium dioxide; copovidone; arginine; maize starch; purified talc; magnesium stearate; propylene glycol - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin. trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea. trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor. trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 2.5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide yellow; propylene glycol; copovidone; colloidal anhydrous silica; arginine; maize starch; purified talc; magnesium stearate; titanium dioxide - trajentamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate, in patients inadequately controlled on metformin alone, or those already being treated and well controlled with the free combination of linagliptin and metformin.,trajentamet is indicated in combination with a sulfonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea.,trajentamet is indicated in combination with an sglt2 inhibitor (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximum tolerated dose of metformin and an sglt2 inhibitor.,trajentamet is indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin and metformin alone do not provide adequate glycaemic control.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; microcrystalline cellulose; carmellose sodium - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. diabex xr 500 may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg; glibenclamide, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; quinoline yellow; iron oxide yellow; iron oxide red; macrogol 4000 - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metformin hydrochloride, quantity: 500 mg; glibenclamide, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - second line treatment of diabetes mellitus type ii in adult patients whose glycaemic control is inadequate after diet and exercise alone and where combined therapy with metformin and glibenclamide is appropriate.